Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Linio Biotech Oy
With
Clinius Ltd
Tience®, a human adipose tissue derivative, is intended to be used in the human body for its original purpose to supplement and replace local extracellular matrix deficiencies in soft tissue, including skin. Tience provides a temporary conductive environment into the injured area. This facilitates the ability of local cells to re-populate the damaged soft tissue and skin area, thereby enabling the deposition of extracellular matrix and repair of the tissue. Tience is authorized for treatment of wounds, scars and soft tissue defects.
The purpose of this study is to determine whether the product is suitable for the treatment of acne scars, and to collect safety data on the use of Tience® in this indication.
Age
18–40
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\-
You may not be if
pregnancy or nursing
cancer or ongoing cancer treatment
an active skin disease
Fitzpatric scale 4-6 skin type
a strong medication used for treating severe acne (e.g., Isotretinoin)
active acne or Herpes
antihistamine medication (if the medication can be paused for 7 days during study visits, participation is possible)
use of biological medications
tendency for excessive scar formation
tendency for urticaria (hives)
systemic medication affecting immunity
autoimmune disease
known disease affecting blood clotting (bleeding or thrombosis tendency) (e.g., von Willebrand disease)
are allergic to the product being studied or any of its ingredients